NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy

Background Viral resistance-associated substitutions (RASs) can develop in the setting of DAAs therapy (i.e., emerging RASs). Long-term monitoring of fibrosis regression after achieving SVR to simiprevir (SMV)/sofosbuvir (SOF) is essential. The aim of this study was to determine the prevalence of ba...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Liver Journal 2021-02, Vol.11 (1), p.13-7
Main Authors: Makhlouf, Nahed A, Farouk, Mohamed, Nafeh, Hanan Mohamed, Hasanain, Ahmad Farooq Alsayed, El-Mokhtar, Mohamed Ahmed, Hetta, Helal F, Mekky, Mohamed A
Format: Article
Language:English
Subjects:
Care and treatment
Fibrosis
Fibrosis regression
Genotype & phenotype
HCV
Hepatitis C
Hepatitis C virus
Infections
Laboratories
Liver
Liver cancer
Liver cirrhosis
Medical research
Medicine, Experimental
Patients
Proteins
RASs
SMV/SOF
Variables
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Viral resistance-associated substitutions (RASs) can develop in the setting of DAAs therapy (i.e., emerging RASs). Long-term monitoring of fibrosis regression after achieving SVR to simiprevir (SMV)/sofosbuvir (SOF) is essential. The aim of this study was to determine the prevalence of baseline and emerging NS34A RASs in chronic HCV patients in Upper Egypt and to assess the impact of SMV/SOF therapy on liver stiffness. Results The enrolled 59 patients had HCV genotype 4a without any baseline RASs in the NS34A region. 96.6% (57/59) of patients achieved sustained virological response (SVR12). Of the two patients who failed to achieve SVR12, one of them developed emerging RASs Q80K in the NS34A region. Seventy-two weeks after SMV/SOF therapy, the percentage of patients with liver fibrosis stage (F2, F3, and F4) decreased from 75.4% before treatment to 42.1% after treatment. The combination of SOF and SMV appeared to be well tolerated. Conclusions All patients had HCV genotype 4a without any baseline RASs in the NS34A region. In addition, there was improvement of non-invasive measures of liver fibrosis in patients who achieved SVR, 72 weeks after SMV/SOF therapy.
ISSN:2090-6218
2090-6226
DOI:10.1186/s43066-021-00080-0